PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy

Background Combination therapy has been explored for advanced head and neck squamous cell carcinoma (HNSCC) owing to the limited efficacy of anti-epidermal growth factor receptor (EGFR) therapy. Increased expression and glycosylation of immune checkpoint molecules in tumors are responsible for cetux...

Full description

Saved in:
Bibliographic Details
Main Authors: Min Li, Yiqi Xu, Yuqing Wang, Xuan Zhou, Mei Mei, Jingxuan Yang, Zhenyue Gao, Ruxin Hu, Yuhong Wang, Zheng Su, Xiaoyue Zhang, Yu Ren
Format: Article
Language:English
Published: BMJ Publishing Group 2021-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/10/e002699.full
Tags: Add Tag
No Tags, Be the first to tag this record!